Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Sandoz Group Ltd ( (CH:SDZ) ).
Sandoz has launched Pyzchiva®, the first ustekinumab biosimilar available in Europe as an autoinjector, enhancing its leadership in immunology biosimilars. This launch is expected to improve patient adherence and quality of life for those with chronic inflammatory diseases, potentially reducing healthcare costs and strengthening Sandoz’s market position.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF45.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz is a global leader in generic and biosimilar medicines, headquartered in Basel, Switzerland. The company is committed to pioneering access for patients, with a diverse portfolio addressing a wide range of diseases. Sandoz employs over 20,000 people worldwide and has a history of significant medical breakthroughs.
Average Trading Volume: 1,375,265
Current Market Cap: CHF17.24B
For detailed information about SDZ stock, go to TipRanks’ Stock Analysis page.